FOXO4-DRI (Proxofim) (10mg) is sold exclusively for laboratory and in-vitro research applications
medical spa Flexible appointments and personalized approach.
In addition, the limit of volumes (25250 l) for nasal administration, influence of nasal pathologic conditions such as rhinitis and common cold on the absorption, and potential for nasal irritation by drug administration in the nasal cavity, are significant factors governing in the choice of the nasal route for drug application (Ozsoy et al., 2009
ProHealth states the product is manufactured in an FDA-registered, GMP-certified facility, which relates to manufacturing standards rather than product approval
Suppression of Pro-inflammatory Cytokines: Research suggests the peptide significantly inhibits the production of TNF-alpha and Interleukin-6 (IL-6), effectively dampening the cytokine storm in experimental models